Homer Pearce, PhD. – Chairman
Homer served in various capacities at Eli Lilly & Company after joining the company in 1979, including Vice President, Cancer Research and Clinical Investigation from 1994 to 2002 and Distinguished Research Fellow, Cancer Research, Lilly Research Laboratories from 2002 to March 2006. He was involved in the development of more than 25 investigational drugs, of which three have resulted in regulatory approvals, including Gemzar® and Alimta®.
Homer was recently named “A Hero of Chemistry” by the American Chemical Society for his role in the discovery and development of the anti-cancer drug Alimta. Homer earned his doctoral degree from Harvard University with Nobel Laureate, E. J. Corey and his bachelor’s degree from Texas A&M University. He is a member of the American Association for Cancer Research, the American Chemical Society and the American Association for the Advancement of Science. He currently serves on several advisory and company boards.
Steve Carchedi — CEO and Member
Steve was previously Chief Executive Officer and President of Cornerstone Pharmaceuticals, an oncology discovery and development company focused on cancer metabolism. He served as the Senior Vice President and President, Commercial Operations (North America) for Mallinckrodt Pharmaceuticals. Having held key positions at several leading multinational pharmaceutical companies, he brings more than 30 years of commercial industry experience focused in Oncology, Neurology, Urology, Endocrinology and Cardiology.
In addition to his industry experience, Steve currently serves on the Board of Directors of Sunesis Pharmaceuticals, and Bionumerik Pharmaceuticals. He also previously served on the board of directors for Cornerstone Pharmaceuticals and Picasso Diagnostics. Steve also served as Co-Chair of the BioNJ Personalized Medicine & Diagnostics Committee Council (CMOC), the Ontario Institute of Cancer Research Commercial Committee (OICR) and the Pharmaceutical Industry Board of the American Pediatric Family Foundation.
Steve received a B.S. in Marketing from West Chester University and an MBA in Marketing from Drexel University.
David Broecker – Member
From 2014 to 2016, David served as the CEO, leading the company through the acceptance of the IND of APX3330. David is an experienced life sciences executive and entrepreneur with a track record of transforming organizations and creating value. He joined the BOD of Apexian in May, 2013 and became CEO in May, 2014. He currently is leading the formation of the Indiana Biosciences Research Institute as Chief Operating Officer and is the executive chairman of Zorion Medical, an early stage medical device company. Over the past several years, David has provided executive leadership and strategic planning to numerous life science start-ups.
David served as Chief Operating Officer, President, and then CEO of Alkermes, Inc. leading the transformation of the company to profitability through the launch of 4 products and advancement of a proprietary pipeline, now advancing into late stage development. Prior to Alkermes, Broecker was an executive at Eli Lilly and Company, working in a variety of global general management positions, product and business development, new product planning, operations, and engineering assignments and experiences.
He received his Bachelor of Arts degree from Wabash College, majoring in chemistry and mathematics and his Master of Science degree in chemical engineering from the Massachusetts Institute of Technology. David also received his Master of Business Administration from the University of Chicago.
Martin Haslanger, PhD. – Member
From 2007 to 2014, Marty served as the CEO leading the company through the discovery of several novel compounds and identification of several potential therapeutic targets for future development. Prior to Apexian, Marty founded Amphora Discovery Corporation in September 2001. As President, CEO, he built the company to be a unique discovery engine with multiple projects at the IND-enabling stage. He then served in the Vice Chairman role from January of 2005 until January 2007.
Marty has three decades of pharmaceutical and biotechnology industry experience. Among those were nine years at Eli Lilly from 1992 to 2001, where he served as Executive Director of Research Technologies and President of Sphinx Labs.
Prior to that, he was Director of Cardiovascular and CNS Medicinal Chemistry at the Schering-Plough Research Institute. He began his pharmaceutical career at the Squibb Institute for Medical Research in Princeton, N.J. He led multiple projects from idea to clinical candidate stage at both Squibb and Schering-Plough.
Marty received his Ph.D. in Organic Chemistry at the University of Michigan and completed a postdoctoral fellowship at Harvard University.
Mark R. Kelley, PhD. – Member
Mark is currently the Betty and Earl Herr Chair in Pediatric Oncology Research and Professor, Departments of Biochemistry & Molecular Biology and Pharmacology & Toxicology,, Indiana University School of Medicine. He is also the Associate Director, Herman B Wells Center for Pediatric Research and the Associate Director for Basic Science Research at the IU Simon Cancer Center.
Mark completed his postdoctoral Fellowship at The Rockefeller University, New York, NY after earning his M.S. and Ph.D. from Louisiana State University, Baton Rouge, LA in 1984.
Mark holds numerous patents related to the use of DNA repair targets for cancer and has published over 166 articles in peer reviewed journals as well as 28 reviews and book chapters in numerous national and international journals. He also serves on the consulting/scientific boards of several biotechnology companies and has and still serves on various NIH/NCI study sections and Cancer Center review panels. He was chair of the Cancer Etiology Study Section at NIH. He has also reviewed for international agencies. He is a member of American Association for the Advancement of Science, American Association for Cancer Research, Society for Pediatric Research, and American Society of Clinical Oncology.
Mark also serves on the editorial board of Frontiers in Bioscience, Journal of Pharmacology and Experimental Therapeutics, Mutation Research; Molecular and Fundamental Mechanisms (Assoc Editor) and Current Molecular Pharmacology.
Richard A. Messmann, M.D., M.H.S., M.Sc. — Chief Medical Officer
Richard is an NCI fellowship-trained medical oncologist with extensive experience in clinical trials in oncology and radiologic imaging. He served as Deputy Associate Director of the NCI Developmental Therapeutics Program (DTP) managing the division’s personnel, natural products group, biological and pharmaceutical laboratories at Ft. Detrick, MD, as well as being an attending physician for DTP Phase I clinical trials. After government service, Richard was an academic oncologist at Michigan State University, heading the breast cancer team as Principal Investigator for several National Surgical Adjuvant Breast and Bowel Project (NSABP) cooperative group trials. His pharmaceutical and biotech experience includes being a clinical research physician at Eli Lilly and Company and as Vice President for Medical Affairs at Endocyte, Inc. where his leadership supported a successful IPO for the company (Feb 2011) and a $1B licensing partnership with Merck (March 2012).
Prior to joining Apexian, Richard was the Chief Medical Officer for ProNAi Therapeutics directing development of a BCL2-targeted therapeutic agent, closing on the largest single round of venture capital funding in Michigan’s history, a series D round of $59.5 million before taking the company public in July 2015 raising $158.4 million in the IPO. He has degrees in electrical and computer engineering (B.S., Oakland University), health science and clinical research (M.H.S., Duke University) and biochemistry and medicine (M.Sc. and M.D., Wayne State University). Residency training included anesthesiology and critical care (Georgetown University and University of Michigan) and Internal Medicine (Michigan State University) where he served as chief resident. Richard is a member of the American Society of Clinical Oncology, American Association for Cancer Research, American Society of Hematology and European Society for Medical Oncology. He is the author of numerous peer-reviewed articles and book chapters.